ãã°ã€ã³ã§çµç¹ã»å¥çŽäŸ¡æ Œãã芧ãã ããã
ãµã€ãºãéžæããŠãã ãã
衚瀺ã倿Žãã
ãã®ååã«ã€ããŠ
å®éšåŒïŒãã«è¡šèšæ³ïŒ:
C25H48N6O8 · xCH4O3S
CASçªå·:
ååé:
560.68 (free base basis)
UNSPSC Code:
41116107
NACRES:
NA.25
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
OK to freeze, desiccated (hygroscopic)
ãã¯ãã«ã«ãµãŒãã¹
ãå°ãã®ããšãããã°ãçµéšè±å¯ãªãã¯ãã«ã«ãµãŒãã¹ããŒã ãã客æ§ããµããŒãããŸãã
ãæäŒãããŸãQuality Segment
description
Merck USA index - 14, 2860
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: chelator
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
color
faint yellow
solubility
water: 50 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
[S](=O)(=O)([O-])C.[N+H3]CCCCCN(O)C(=O)CCC(=O)NCCCCCN(O)C(=O)CCC(=O)NCCCCCN(O)C(=O)C
InChI
1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
InChI key
IDDIJAWJANBQLJ-UHFFFAOYSA-N
General description
Iron chelating agent. Completely protects against dopamine-induced cell death. Has also been shown to interfere with hydroxyl radical formation, which mediates tissue damage in several disease states. Shows anti-proliferative effect on vascular smooth muscle cells in vitro and in vivo. Can also inhibit the oxidative chemistry of peroxynitrite by reaction of the hydroxamic acid moieties with trans-peroxynitrous acid.
Application
- Defective ferritinophagy and imbalanced iron metabolism in PBDE-47-triggered neuronal ferroptosis and salvage by Canolol.: This study explores the application of Deferoxamine Mesylate in mitigating iron overload and oxidative stress in neuronal cells, demonstrating its potential in neuroprotection and treatment strategies for neurodegenerative disorders (Wang et al., 2024).
- Ferroptosis resists intracellular Vibrio splendidus AJ01 mediated by ferroportin in sea cucumber Apostichopus japonicus.: The study demonstrates the potential of Deferoxamine Mesylate in aquatic animal health, particularly in enhancing the resistance against bacterial infections by modulating ferroptosis pathways (Wang et al., 2024).
Other Notes
Bergeron, R.J., et al. 1996. J. Med. Chem. 39, 1575.
Ben-Shachar, D., et al. 1995. J. Neurochem. 64, 718.
Denicola, A., et al. 1995. Free Radic. Biol. Med. 19, 11.
Dzwigaj, S., and pererat, H., 1995. Free Radic. Res.14, 103.
Dang, S., et al. 1994. Res. Commun. Mol. Pathol. Pharmacol. 86, 43.
Porreca, E., et al. 1994. Arterioscler. Thromb. 14, 299.
Ben-Shachar, D., et al. 1995. J. Neurochem. 64, 718.
Denicola, A., et al. 1995. Free Radic. Biol. Med. 19, 11.
Dzwigaj, S., and pererat, H., 1995. Free Radic. Res.14, 103.
Dang, S., et al. 1994. Res. Commun. Mol. Pathol. Pharmacol. 86, 43.
Porreca, E., et al. 1994. Arterioscler. Thromb. 14, 299.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful & Carcinogenic / Teratogenic (E)
ä¿ç®¡åé¡
11 - Combustible Solids
äžäœäœãèµ·ããŠããã®ïŒ
WGK 2
åŒç«ç¹ (F)
Not applicable
åŒç«ç¹ïŒÂ°CïŒ
Not applicable
ææ°ããŒãžã§ã³ã®ãããããéžæããŠãã ããïŒ
以åãã®è£œåãè³Œå ¥ããã ããããšãããå Žå
ææžã©ã€ãã©ãªã§ãæè¿è³Œå ¥ãã補åã®ææžãæ€çŽ¢ã§ããŸãã